Gland Pharma Ltd

Gland Pharma Ltd has announced the closure of its trading window in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The window will be shut from Saturday, June 27, 2026, until 48 hours after the declaration of the company's unaudited financial results for the quarter ending June 30, 2026. The specific date for the board meeting to approve these results will be communicated later. This measure is standard practice to prevent insider trading during sensitive financial reporting periods.

Gland Pharma Ltd announced the resignation of its Independent Director, Mr. Satyanarayana Murthy Chavali, effective June 15, 2026. The resignation stems from a potential conflict of interest, as Mr. Chavali is a promoter and director of another company planning to enter a business segment that may overlap with Gland Pharma's proposed activities. The company has provided the necessary disclosures as per SEBI LODR Regulations, 2015.

Gland Pharma Limited's Board of Directors met on June 15, 2026, approving key management changes. Mr. Udo Jahannes Vetter was re-appointed as an Independent Director for a second five-year term. Mr. William Robert Keller was appointed as an Additional Director (Non-Executive - Independent). Mr. Satyanarayana Murthy Chavali resigned as an Independent Director due to a potential future conflict of interest. Following Mr. Chavali's resignation, Mr. Essaji Goolam Vahanvati was appointed to the Board of Gland Pharma International Pte. Ltd. The Board committees were also realigned.

Gland Pharma Limited announced significant changes to its Board of Directors following a meeting on June 15, 2026. Mr. Udo Jahannes Vetter was re-appointed as an Independent Director for a second five-year term. Additionally, Mr. William Robert Keller was appointed as an Additional Director (Non-Executive - Independent Director). The company also accepted the resignation of Independent Director Mr. Satyanarayana Murthy Chavali due to a potential conflict of interest. Consequently, Mr. Essaji Goolam Vahanvati was appointed as a Director on the Board of Gland Pharma International Pte. Ltd (Material Subsidiary). Board committees have also been realigned.

Gland Pharma Limited announced a series of board changes during its meeting on June 15, 2026. Mr. C.S.N. Murthy resigned as an Independent Director due to a potential conflict of interest. The board accepted his resignation, effective the close of business hours on June 15, 2026, and expressed appreciation for his contributions since November 20, 2018. Concurrently, Mr. William Robert Keller was appointed as an Additional Director (Non-Executive - Independent Director). Additionally, Mr. Essaji Goolam Vahanvati was appointed as a Director on the Board of Gland Pharma International Pte. Ltd. The company also re-appointed Mr. Udo Jahannes Vetter as an Independent Director for a second term.

Gland Pharma Ltd has granted 690,019 employee stock options to 124 employees under its ESOP 2025 scheme. The grant was approved by the ESOP Compensation Committee on May 15, 2026, and adheres to SEBI regulations. 455,413 options are priced at ₹934.15 each (50% of the closing price on May 15, 2026), and 234,606 options are priced at ₹1 each. The options will vest in three tranches: 34% on May 15, 2027, 33% on May 15, 2028, and 33% on May 15, 2029, and can be exercised within two years of vesting.

Gland Pharma Ltd will hold its 48th Annual General Meeting on August 25, 2026, via video conferencing. The board approved the audited financial results for the year ended March 31, 2026, with an unmodified opinion from the statutory auditors. A final dividend of ₹20 (2000%) per equity share of ₹1 each for FY26 was recommended, with a record date of August 11, 2026, for determining eligibility.

Gland Pharma Ltd announced its Q4FY26 financial results, reporting a 22% YoY increase in revenue and a 97% YoY increase in adjusted PAT. The company's revenue from operations stood at ₹17,428 million. The Board recommended a final dividend of ₹20 per share. CDMO business contributed 46% of revenues and grew by 36% year-on-year in Q4FY26.

Gland Pharma Ltd's Board of Directors has approved a final dividend of ₹20 per equity share (2000% on face value of ₹1) for the financial year 2025-26, subject to shareholder approval at the 48th Annual General Meeting (AGM). The dividend will be paid within 30 days of AGM approval. The record date for determining eligibility for the dividend is set for August 11, 2026. The 48th AGM will be held via video conferencing on August 25, 2026.

Gland Pharma Ltd has fixed August 11, 2026, as the record date for determining shareholders' eligibility for the final dividend of ₹20 (2000%) per equity share of ₹1 each for the financial year 2025-26. The dividend, upon shareholder approval, will be paid within 30 days from the date of the 48th Annual General Meeting (AGM), scheduled for August 25, 2026, via video conferencing.